Stockreport

FDA Grants Priority Review for Takeda (TAK) and Protagonist's Rusfertide in PV Treatment [Yahoo! Finance]

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)  (TAK) 
PDF announced that the US FDA accepted the New Drug Application and granted Priority Review for rusfertide. This investigational, first-in-class hepcidin mimetic is intended [Read more]